Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2250 Target Snapshot

Tyrosine-protein kinase Blk · SINGLE PROTEIN · Homo sapiens

1,930Compounds
463Assays
33Approved Drugs
1,157.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P51451. Use UniProt P51451 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P51451 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase Blk as ChEMBL target CHEMBL2250, mapped to UniProt P51451. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase Blk
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2250
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P51451
Tyrosine-protein kinase Blk
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tyrosine-protein kinase Blk is the right protein anchor across sources, using UniProt P51451 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein kinase Blk
UniProt AccessionP51451
Component TypeProtein
Sequence Length505 aa

Tyrosine-protein kinase Blk

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Tyrosine-protein kinase Blk, mapped to UniProt P51451. Sequence length is 505 aa.

Mapped IDP51451
Review nameTyrosine-protein kinase Blk
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

33
Approved
14
Phase III
20
Phase II
8
Phase I
Assay Mix

Activity Type Distribution

IC50330.0
KI668.0
EC5025.0
KD134.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1873475 10.0 IC50 0.1 Approved
CHEMBL4211949 9.7 IC50 0.2 Preclinical
CHEMBL3647967 9.7 IC50 0.2 Preclinical
CHEMBL5416410 9.68 Kd 0.21 Approved
CHEMBL5189379 9.3 IC50 0.5 Preclinical
CHEMBL1873475 9.25 Kd 0.56 Approved
CHEMBL4464404 9.15 IC50 0.7 Preclinical
CHEMBL1994938 9.1 Ki 0.7943 Preclinical
CHEMBL249097 9.0 Kd 1.0 Preclinical
CHEMBL1988717 9.0 Ki 1.0 Preclinical
Distribution

pChEMBL Value Distribution

20
5.0
52
5.5
125
6.0
122
6.5
115
7.0
73
7.5
33
8.0
23
8.5
13
9.0
6
9.5
pChEMBL
Approved Drugs

Approved Drugs

QUIZARTINIB
CHEMBL576982
Approved 2023
BELUMOSUDIL
CHEMBL2005186
Approved 2021
FEDRATINIB
CHEMBL1287853
Approved 2019
ZANUBRUTINIB
CHEMBL3936761
Approved 2019
ENTRECTINIB
CHEMBL1983268
Approved 2019
MIDOSTAURIN
CHEMBL608533
Approved 2017
BRIGATINIB
CHEMBL3545311
Approved 2017
NERATINIB
CHEMBL180022
Approved 2017
ACALABRUTINIB
CHEMBL3707348
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
IBRUTINIB
CHEMBL1873475
Approved 2013
AFATINIB
CHEMBL1173655
Approved 2013
AFATINIB DIMALEATE
CHEMBL2105712
Approved 2013
BOSUTINIB
CHEMBL288441
Approved 2012
VANDETANIB
CHEMBL24828
Approved 2011
CRIZOTINIB
CHEMBL601719
Approved 2011
NILOTINIB
CHEMBL255863
Approved 2007
DASATINIB
CHEMBL5416410
Approved 2006
SUNITINIB
CHEMBL535
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
ERLOTINIB
CHEMBL553
Approved 2004
GEFITINIB
CHEMBL939
Approved 2003
IMATINIB
CHEMBL941
Approved 2001
Assay Landscape

Assay Landscape

463
Total Assays
283
Tested Compounds
3
Assay Types
Binding — 457 assays, 283 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 350 200 7.0
assay format 58 35 6.9
cell-based format 45 48 7.1
subcellular format 4 0
ADME — 4 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 0
single protein format 2 2 9.3
Functional — 2 assays, 225 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 224 6.9
cell-based format 1 1 6.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine